86 related articles for article (PubMed ID: 19118710)
1. Pharmacokinetics.
Byeon SH; Kang SY
Ophthalmology; 2009 Jan; 116(1):168-9; author reply 169-70. PubMed ID: 19118710
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.
Abrishami M; Zarei-Ghanavati S; Soroush D; Rouhbakhsh M; Jaafari MR; Malaekeh-Nikouei B
Retina; 2009 May; 29(5):699-703. PubMed ID: 19430280
[TBL] [Abstract][Full Text] [Related]
7. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
Krohne TU; Eter N; Holz FG; Meyer CH
Am J Ophthalmol; 2008 Oct; 146(4):508-12. PubMed ID: 18635152
[TBL] [Abstract][Full Text] [Related]
8. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit.
Kim MJ; Han ES; Kim J; Kim TW
J Ocul Pharmacol Ther; 2010 Feb; 26(1):49-53. PubMed ID: 20148650
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.
Meyer CH; Krohne TU; Holz FG
Acta Ophthalmol; 2012 Feb; 90(1):68-70. PubMed ID: 20163369
[TBL] [Abstract][Full Text] [Related]
10. Predicted biologic activity of intravitreal bevacizumab.
Stewart MW
Retina; 2007; 27(9):1196-200. PubMed ID: 18046224
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
la Cour M
Acta Ophthalmol Scand; 2007 Feb; 85(1):2-4. PubMed ID: 17244202
[No Abstract] [Full Text] [Related]
12. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
14. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of rituximab following an intravitreal injection.
Kim H; Csaky KG; Chan CC; Bungay PM; Lutz RJ; Dedrick RL; Yuan P; Rosenberg J; Grillo-Lopez AJ; Wilson WH; Robinson MR
Exp Eye Res; 2006 May; 82(5):760-6. PubMed ID: 16289160
[TBL] [Abstract][Full Text] [Related]
16. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.
Beer PM; Wong SJ; Hammad AM; Falk NS; O'Malley MR; Khan S
Retina; 2006 Oct; 26(8):871-6. PubMed ID: 17031285
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
[TBL] [Abstract][Full Text] [Related]
18. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
Ottiger M; Thiel MA; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):779-86. PubMed ID: 18757511
[TBL] [Abstract][Full Text] [Related]
19. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.
Kakinoki M; Sawada O; Sawada T; Saishin Y; Kawamura H; Ohji M
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5877-80. PubMed ID: 22836776
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.
Meyer CH; Krohne TU; Holz FG
Retina; 2011 Oct; 31(9):1877-84. PubMed ID: 21738089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
